AI Article Synopsis
Article Abstract
Background: Gabapentinoids, such as gabapentin and pregabalin, are opioid substitutes commonly included in perioperative multimodal analgesia regimens. We investigated whether the initiation of gabapentin and pregabalin during the perioperative period have varying effects on the adverse renal outcomes.
Methods: This study included adult participants who received surgery in the INSPIRE database. The exposure of interest was the initiation of pregabalin or gabapentin during the perioperative period. The primary outcome was renal function decline. Secondary outcomes included incident chronic kidney disease (CKD), hospital-acquired acute kidney injury (AKI), and in-hospital mortality. We conducted a propensity score to balance the baseline characteristics. Cox proportional hazard regression was used to estimate the hazard ratio (HR) of the initiation of gabapentin compared with pregabalin.
Results: Among 640 pairs of pregabalin and gabapentin initiators in the matched cohort, the initiation of gabapentin was associated with a higher risk of kidney function decline (HR, 1.40; 95% confidence interval [CI], 1.04-1.89) as compared with pregabalin. After excluding participants who were diagnosed with CKD at the baseline, the initiation of gabapentin was associated with a higher risk of incident CKD (HR, 1.46; 95% CI, 1.03-2.05) as compared with pregabalin. For the in-hospital outcomes, the proportion of AKI and mortality were similar between participants initiating gabapentin and pregabalin. In addition, the risk of kidney function decline did not vary across each subgroup.
Conclusion: The initiation of gabapentin during the perioperative period was associated with a higher risk of kidney function decline and incident CKD as compared with pregabalin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666351 | PMC |
| http://dx.doi.org/10.3389/fmed.2024.1488773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of perioperative initiation of gabapentin versus pregabalin with kidney function: a target trial emulation study.
Front Med (Lausanne)
December 2024
Department of Nephrology, Peking University Third Hospital, Beijing, China.
Background: Gabapentinoids, such as gabapentin and pregabalin, are opioid substitutes commonly included in perioperative multimodal analgesia regimens. We investigated whether the initiation of gabapentin and pregabalin during the perioperative period have varying effects on the adverse renal outcomes.
Methods: This study included adult participants who received surgery in the INSPIRE database.
[Opioid prescriptions for insured individuals without cancer in Germany: data from the BARMER].
Schmerz
December 2024
PMV Forschungsgruppe an der Medizinischen Fakultät und Universitätsklinikum Köln, Universität zu Köln, Köln, Deutschland.
Background: The importance of opioids in the treatment of non-cancer pain is under debate. No current data are available from Germany on the prevalence of opioid treatment for non-cancer pain.
Aim Of The Study: Data on the prevalence of short- and long-term opioid prescriptions for patients without cancer, prescribed agents, co-medication, specialty of prescribing physicians, demographic and clinical characteristics of patients.
Intraoperative Pain Management for Treatment-Resistant Complex Regional Pain Syndrome: A Case Report.
Cureus
November 2024
Anesthesiology, Jackson Memorial Hospital, Miami, USA.
Complex regional pain syndrome (CRPS) is a chronic neuropathic pain disorder often following trauma, associated with severe pain and autonomic disturbances in the affected limbs. Managing CRPS is challenging due to the lack of FDA-approved medications, often requiring off-label treatments. Traditional options like nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids show limited efficacy, while adjunctive treatments such as gabapentin, antidepressants, and bisphosphonates are increasingly favored.
View Article and Find Full Text PDFA Nursing Home Clinician Survey to Explain Gabapentinoid Increases.
J Am Med Dir Assoc
November 2024
Department of Family Medicine and Population Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA; Larry A. Green Center, Richmond, VA, USA.
Objectives: Survey nursing home (NH) clinicians about the indications for NH gabapentinoid use, the factors driving increased prescribing, and their experiences with gabapentinoid deprescribing.
Design: Online clinician survey.
Setting And Participants: NH clinicians prescribing gabapentinoids in US NHs.
Assessing the feasibility of the GOTT (Gabapentinoid and Opioid Tapering Toolkit) in a primary care setting in North-East England.
Br J Pain
October 2024
Department of Biosciences, Wolfson Research Institute for Health and Wellbeing, Durham University, Durham, UK.
Objective: To assess the feasibility and possible impacts of implementation of systematic non-pharmacological interventions to reduce the level of prescribing of opioid and gabapentinoid analgesics for chronic non-cancer pain (CNCP), particularly high-dose prescriptions, through a proof-of-concept study in a deprived area (second lowest decile) primary care practice in North-East England.
Participant: Twenty-five primary care staff (clinical and non-clinical) of which 18 clinicians received the intervention.
Intervention Used In This Study Practice Known As Gott Gabapentinoid And Opioid Toolkit: All clinicians received an educational skills programme to support patient pain self-management, tailored on the clinicians' self-assessment of their learning needs, embedding both clinician skill learning and patient self-care resources for rapid access within consultations into a GP clinical management computer system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!